Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 18/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | PYGL | P06737 | 2/20 | 0.41 |
| ▸ | PYGM | P11217 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19228225 | 1.00 | RIPK1 (0.48) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19207683 | 1.00 | RIPK1 (0.48) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL29415660 | 1.00 | RIPK1 (0.48) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19228222 | 1.00 | RIPK1 (0.48) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19207698 | 1.00 | RIPK1 (0.48) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19207646 | 1.00 | RIPK1 (0.48) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19255019 | 0.90 | RIPK1 (0.50) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19255053 | 0.90 | RIPK1 (0.50) | RIPK1NR1I2CYP2C9PYGLPYGM | |
| SCHEMBL19255504 | 0.86 | RIPK1 (0.46) | RIPK1NR1I2CYP2C9 | |
| SCHEMBL19228550 | 0.84 | RIPK1 (0.69) | RIPK1NR1I2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | DENALI THERAPEUTICS INC. | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180099981-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | PIK3CA, PLK1, PIK3CB | RIPK1 416/4885NR1I2 4071/4885CYP2C9 3496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.